TELMISARTAN IN THE TREATMENT OF ARTERIAL HYPERTENSION. CASE STUDY

TELMISARTAN IN THE TREATMENT OF ARTERIAL HYPERTENSION. CASE STUDY

Show other versions (1)

<p>Data on angiotensin II receptor blockers, one of the main drug classes used in cardiology , are presented. The advantages of this drugs class are highlighted with the focus on telmisartan. Additionally clinical example of successful telmisartan application in patients with hypertension, hig...

Full description

Bibliographic Details
Main Authors:	V. I. Podzolkov, A. I. Tarzimanova
Format:	Article
Language:	English
Published:	Столичная издательская компания 2015-12-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	блокаторы рецепторов ангиотензина-II телмисартан артериальная гипертензия
Online Access:	http://www.rpcardio.ru/jour/article/view/559

Similar Items

Cardiometabolic properties of telmisartan: new perspectives for use
by: O. M. Drapkina, et al.
Published: (2015-12-01)

Vozmozhnosti obespecheniya nefroprotektsii na fone blokady retseptorov angiotenzina II kandesartanom u bol'nykh arterial'noy gipertoniey
by: N M Chikhladze, et al.
Published: (2004-03-01)

Angioprotection role in arterial hypertension treatment: focus on olmesartan
by: D. V. Nebieridze, et al.
Published: (2012-10-01)

Treatment of hypertension in children and adolescents
by: I. V. Leontyeva
Published: (2019-03-01)

IRBESARTAN IN THE CLINICAL PRACTICE
by: V. I. Podzolkov, et al.
Published: (2015-09-01)

Advantages of telmisartan pharmacotherapy in elderly patients with arterial hypertension and metabolic syndrome who have suffered an ischemic stroke
by: O. A. Osipova, et al.
Published: (2022-10-01)

Treatment of hypertension in obese patients: focus on telmisartan
by: I. E. Deneka, et al.
Published: (2018-12-01)

Arterial hypertension and Type 2 diabetes mellitus: any benefits for angiotensin II receptor blockers?
by: V. V. Fomin, et al.
Published: (2007-06-01)

The use of telmisartan in patients with refractory arterial hypertension and obesity
by: I. Е. Deneka, et al.
Published: (2019-03-01)

Telmisartan in the hypertension treatment: from pharmacological characteristics to clinical benefits
by: E. V. Sayutina, et al.
Published: (2020-03-01)

Left ventricular hypertrophy: prognostic value, pathogenesis, possible remodeling: focusing on angiotensin receptor antagonists
by: M. D. Smirnova, et al.
Published: (2007-12-01)

INACTIVATION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM. WHICH CLASS OF ANTIHYPERTENSIVE MEDICINE PRODUCTS TO PREFER?
by: S. V. Stolov
Published: (2020-12-01)

Inflammation role in atrial fibrillation pathogenesis
by: A. I. Tarzimanova, et al.
Published: (1970-01-01)

A META-ANALYSIS REPORTING EFFECTS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS IN PATIENTSWITHOUT HEART FAILURE
by: G. Savarese, et al.
Published: (2015-09-01)

Current approach to antihypertensive therapy
by: M. V. Kuznetsova
Published: (2015-12-01)

IS IT WORTH TO DISCONTINUE DRUGS BLOCKING THE ACTIVITY OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN THE PERI-OPERATIVE PERIOD?
by: V. V. Lomivorotov, et al.
Published: (2018-07-01)

COMBINATION THERAPY OF ARTERIAL HYPERTENSION - OUR EXPECTATIONS
by: O. D. Ostroumova, et al.
Published: (2013-03-01)

Endothelial functional activity and circadian blood pressure dynamics in hypertensive patients treated with angiotensin receptor antagonists
by: N. G. Poteshkina, et al.
Published: (2011-10-01)

Acquisition of renin-angiotensin-aldosterone system inhibitors for the treatment of cardiovascular diseases in regions of the Far Eastern Federal District
by: M. S. Soboleva, et al.
Published: (2020-04-01)

THE EFFECTIVENESS OF LERCANIDIPINE IN REDUCING THE RISK OF ARTERIAL HYPERTENSION COMPLICATIONS
by: E. EL. Trisvetova
Published: (2015-09-01)

Farmakologicheskaya blokada angiotenzinovykh retseptorov v lechenii arterial'noy gipertenzii: ot saralazina do sartanov
by: Viktor Viktorovich Fomin, et al.
Published: (2013-09-01)

Prostacyclin receptor agonist selexipag in a patient with high-risk idiopathic pulmonary arterial hypertension: a case report
by: E. A. Rezukhina, et al.
Published: (2021-09-01)

Arterial hypertension in women with climacteric syndrome
by: V. I. Podzolkov, et al.
Published: (2005-10-01)

Angiotensin II receptor blockers and cardiorenal risk management: Irbesartan status
by: V. V. Fomin
Published: (2013-12-01)

EXPERIENCE OF USING THE NONSELECTIVE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
by: M. A. Simakova, et al.
Published: (2018-04-01)

Lercanidipine in general practice settings: safety and effectiveness. The LAPSE Study results
by: N. R. Robles, et al.
Published: (2010-10-01)

OPPORTUNITIES FOR OPTIMIZATION OF DRUG THERAPY BY ENDOTHELIN RECEPTOR ANTAGONISTS FOR THE PATIENT WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION AND ATRIAL SEPTOSTOMY
by: V. V. Gramovich, et al.
Published: (2018-12-01)

Developing approaches to treating arterial hypertension in regard to possible pathways of angiotensin II synthesis
by: N. M. Chikhladze, et al.
Published: (2006-04-01)

TELMISARTAN IN THE TREATMENT OF ARTERIAL HYPERTENSION. CASE STUDY
by: V. I. Podzolkov, et al.
Published: (2015-12-01)

THE NEW FIXED COMBINATION OF AMLODIPINE AND RAMIPRIL IN THE TREATMENT OF HYPERTENSION
by: V. I. Podzolkov, et al.
Published: (2015-09-01)

POSSIBILITY OF ANGIOTENSIN RECEPTOR BLOCKERS IN OPTIMIZING OF ANTIHYPERTENSIVE PHARMACOTHERAPY IN PATIENTS AFTER STROK
by: Z M. Sizova
Published: (2015-09-01)

Lechenie patsienta s arterial'noy gipertenziey i gipertrofiey levogo zheludochka
by: I E Chazova, et al.
Published: (2006-03-01)

Portopulmonary hypertension in a child
by: D. I. Sadykova, et al.
Published: (2016-11-01)

Essential arterial hypertension in women, or female arterial hypertension?
by: V. I. Podzolkov, et al.
Published: (2012-02-01)

ACE INHIBITORS IN ARTERIAL HYPERTENSION TREATMENT: FOCUS ON LISINOPRIL
by: V. I. Podzolkov, et al.
Published: (2016-01-01)

Pharmacokinetic and Bioequivalence Study of Telzap AM<sup>®</sup> (Telmisartan/amlodipine Fixed-dose Combination) and Coadministered Mikardis<sup>®</sup> (Telmisartan) and Norvask<sup>®</sup> (Amlodipine) in Healthy Subjects
by: V. Kubesh, et al.
Published: (2020-11-01)

OPTIMIZATION OF SPECIFIC THERAPY FOR PULMONARY ARTERIAL HYPERTENSION: THE POSSIBILITIES OF USING ENDOTHELIN RECEPTOR ANTAGONISTS
by: T. V. Martynyuk, et al.
Published: (2017-06-01)

The choice of combination antihypertensive therapy in patients with type 2 diabetes
by: O. A. Koshelskaya, et al.
Published: (2015-12-01)

RENAL DENERVATION IN RESISTANT ARTERIAL HYPERTENSION
by: V. A. Sulimov, et al.
Published: (2015-09-01)

Olmesartan: vasoprotective effects and reducing the risk of vascular accidents
by: O. D. Ostroumova, et al.
Published: (2014-12-01)